Serological response to vaccination in post-acute sequelae of COVID.
Serological response to vaccination in post-acute sequelae of COVID.
复制标题
DOI：
10.1186/s12879-023-08060-y
复制
发表时间：
2023-02-16
影响因子：
3.7
通讯作者：
Le, Catherine N. N.
中科院分区：
文献类型：
--
作者：
Joung, Sandy;Weber, Brittany;Wu, Min;Liu, Yunxian;Tang, Amber B. B.;Driver, Matthew;Sternbach, Sarah;Wynter, Timothy;Hoang, Amy;Barajas, Denisse;Kao, Yu Hung;Khuu, Briana;Bravo, Michelle;Masoom, Hibah;Tran, Teresa;Sun, Nancy;Botting, Patrick G.;Claggett, Brian L.;Prostko, John C.;Frias, Edwin C.;Stewart, James L.;Robertson, Jackie;Kwan, Alan C.;Torossian, Mariam;Pedraza, Isabel;Sterling, Carina;Goldzweig, Caroline;Oft, Jillian;Zabner, Rachel;Fert-Bober, Justyna;Ebinger, Joseph E.;Sobhani, Kimia;Cheng, Susan;Le, Catherine N. N.
具有COVID急性后后遗症（PASC）的个体可能具有持续的免疫激活，这将其与从COVID中恢复而无临床后遗症的个体区分开来。为了研究体液免疫激活在这方面是如何变化的，我们比较了PASC患者与先前未患PASC的COVID康复者的疫苗引起的血清学反应模式。我们前瞻性研究了245名临床诊断为PASC的成年人和86名成功从先前的COVID中恢复的成年人。所有参与者在首次接种COVID疫苗（单剂量或双剂量方案）之前或之后检测了对SARS-CoV-2的免疫测量，包括抗刺突（IgG-S和IgM-S）和抗核衣壳（IgG-N）抗体以及IgG-S血管紧张素转换酶2 （ACE2）结合水平。我们使用未调整和多变量调整的回归分析来检验PASC与covid - 19恢复状态与疫苗接种后体液免疫测量的关系。与covid - 19恢复的个体相比，PASC个体接种疫苗后IgG-S抗体水平持续较高（IgG-S对数中位数为3.98比3.74,P < 0.001）， ACE2结合水平也有类似的结果（中位数为99.1比98.2,P = 0.044）。PASC疫苗接种后IgM-S反应减弱，但随着时间的推移保持不变（P = 0.33），而COVID恢复后IgM-S反应预期会随着时间的推移而下降（P = 0.002）。当考虑到人口统计学和临床变量，包括指数感染严重程度和合并症负担时，研究结果保持一致。我们发现了将PASC与恢复的COVID区分开来的异常免疫反应的证据。这种异常的特征是过度的IgG-S激活和ACE2结合，以及与延迟或功能失调的免疫球蛋白类转换一致的结果，所有这些都被疫苗激发所掩盖。这些结果表明，除了作为潜在的干预靶点外，异常免疫反应的测量可能为诊断和区分PASC与非PASC表型提供了有希望的工具。在线版本包含补充材料，可在10.1186/s12879-023-08060-y获得。
Individuals with post-acute sequelae of COVID (PASC) may have a persistence in immune activation that differentiates them from individuals who have recovered from COVID without clinical sequelae. To investigate how humoral immune activation may vary in this regard, we compared patterns of vaccine-provoked serological response in patients with PASC compared to individuals recovered from prior COVID without PASC. We prospectively studied 245 adults clinically diagnosed with PASC and 86 adults successfully recovered from prior COVID. All participants had measures of humoral immunity to SARS-CoV-2 assayed before or after receiving their first-ever administration of COVID vaccination (either single-dose or two-dose regimen), including anti-spike (IgG-S and IgM-S) and anti-nucleocapsid (IgG-N) antibodies as well as IgG-S angiotensin-converting enzyme 2 (ACE2) binding levels. We used unadjusted and multivariable-adjusted regression analyses to examine the association of PASC compared to COVID-recovered status with post-vaccination measures of humoral immunity. Individuals with PASC mounted consistently higher post-vaccination IgG-S antibody levels when compared to COVID-recovered (median log IgG-S 3.98 versus 3.74, P < 0.001), with similar results seen for ACE2 binding levels (median 99.1 versus 98.2, P = 0.044). The post-vaccination IgM-S response in PASC was attenuated but persistently unchanged over time (P = 0.33), compared to in COVID recovery wherein the IgM-S response expectedly decreased over time (P = 0.002). Findings remained consistent when accounting for demographic and clinical variables including indices of index infection severity and comorbidity burden. We found evidence of aberrant immune response distinguishing PASC from recovered COVID. This aberrancy is marked by excess IgG-S activation and ACE2 binding along with findings consistent with a delayed or dysfunctional immunoglobulin class switching, all of which is unmasked by vaccine provocation. These results suggest that measures of aberrant immune response may offer promise as tools for diagnosing and distinguishing PASC from non-PASC phenotypes, in addition to serving as potential targets for intervention. The online version contains supplementary material available at 10.1186/s12879-023-08060-y.
登录
查看更多内容
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
与学术医学中心的抗体反应变化有关BNT162B2 COVID-19的抗体反应的变化相关的人口和临床特征：纵向队列分析。
影响因子：
2.9
作者：
Ebinger, Joseph E.;Joung, Sandy;Liu, Yunxian;Wu, Min;Weber, Brittany;Claggett, Brian;Botting, Patrick G.;Sun, Nancy;Driver, Matthew;Kao, Yu Hung;Khuu, Briana;Wynter, Timothy;Nguyen, Trevor-Trung;Alotaibi, Mona;Prostko, John C.;Frias, Edwin C.;Stewart, James L.;Goodridge, Helen S.;Chen, Peter;Jordan, Stanley C.;Jain, Mohit;Sharma, Sonia;Fert-Bober, Justyna;Van Eyk, Jennifer E.;Minissian, Margo B.;Arditi, Moshe;Melmed, Gil Y.;Braun, Jonathan G.;McGovern, Dermot P. B.;Cheng, Susan;Sobhani, Kimia
通讯作者：
Sobhani, Kimia
影响因子：
7.3
作者：
Ramakrishnan RK;Kashour T;Hamid Q;Halwani R;Tleyjeh IM
通讯作者：
Tleyjeh IM
DOI：
10.15585/mmwr.mm7038e1
发表时间：
2021-09-24
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Self WH;Tenforde MW;Rhoads JP;Gaglani M;Ginde AA;Douin DJ;Olson SM;Talbot HK;Casey JD;Mohr NM;Zepeski A;McNeal T;Ghamande S;Gibbs KW;Files DC;Hager DN;Shehu A;Prekker ME;Erickson HL;Gong MN;Mohamed A;Henning DJ;Steingrub JS;Peltan ID;Brown SM;Martin ET;Monto AS;Khan A;Hough CL;Busse LW;Ten Lohuis CC;Duggal A;Wilson JG;Gordon AJ;Qadir N;Chang SY;Mallow C;Rivas C;Babcock HM;Kwon JH;Exline MC;Halasa N;Chappell JD;Lauring AS;Grijalva CG;Rice TW;Jones ID;Stubblefield WB;Baughman A;Womack KN;Lindsell CJ;Hart KW;Zhu Y;Mills L;Lester SN;Stumpf MM;Naioti EA;Kobayashi M;Verani JR;Thornburg NJ;Patel MM;IVY Network
通讯作者：
IVY Network